Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Commentary|Videos|December 10, 2024
Dr Poh on the Preliminary Efficacy of Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma
Author(s)Christina Poh, MD
Christina Poh, MD, discusses results from the phase 3 inMIND study of tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.
Advertisement
Christina Poh, MD, assistant professor, University of Washington, Fred Hutchinson Cancer Center, discusses results from the phase 3 inMIND study (NCT04680052) of tafasitamab (Monjuvi) plus lenalidomide (Revlimid) and rituximab (Rituxan) for relapsed/refractory follicular lymphoma. Results from the study were presented at the
Advertisement
Related to this article
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
5